Author

Patricia Zwierzchowski

Observed name: P Zwierzchowski

Institution: Zymeworks (Canada)

Observed institution: Zymeworks (Canada)

ORCID: 0000-0002-0087-6446

Observed ORCID: 0000-0002-0087-6446

OpenAlex ID: A5034659490

An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity

2023 · Nina E. Weisser, Mario Sanches, et al. · Nature Communications · 209

Abstract P6-17-13: ZW49, a HER2 targeted biparatopic antibody drug conjugate for the treatment of HER2 expressing cancers

2019 · KJ Hamblett, SD Barnscher, et al. · Cancer Research · 58

Abstract 1788: Increasing the therapeutic index of IL12 by engineering for tumor specific protease activation

2021 · Jennifer Leah Bishop, Ryan Blackler, et al. · Cancer Research · 4

Abstract 5121: TriTCE Co-stim, next generation costimulatory trispecific T cell engagers for the treatment of solid tumors

2023 · Lisa Newhook, Purva P. Bhojane, et al. · Cancer Research · 3

Abstract 3503: ZW171, a differentiated 2+1 T cell-engaging bispecific antibody with antitumor activity in a range of mesothelin-expressing cancers

2025 · Nicole J. Afacan, Patricia Zwierzchowski, et al. · Cancer Research · 1

Abstract 2982: TriTCE CPI, next generation trispecific T cell engagers with integrated checkpoint inhibition (CPI) for the treatment of solid tumors

2023 · Maya C. Poffenberger, Meghan M. Verstraete, et al. · Cancer Research · 1

1196 TriTCE Co-stim: a differentiated T cell engager platform with conditional cis CD28 co-stimulation is transferable to diverse targeting strategies

2025 · Chayne L Piscitelli, Diego Perez Escanda, et al. · Journal for ImmunoTherapy of Cancer

Abstract 2942: ZW171, a T cell-engaging, bispecific antibody for the treatment of mesothelin-expressing solid tumors

2023 · Nicole J. Afacan, Chayne Piscitelli, et al. · Cancer Research

Works count: 8

Citation count: 276

H-index: 3

I10-index: 2